Pfizer's maternal RSV vaccine approved to help protect newborns
Pfizer’s RSV vaccine is now approved to help protect newborns when administered to women between 32 and 36 weeks of pregnancy.
The FDA approval adds to a growing armamentarium against respiratory syncytial virus, a respiratory disease that puts around 58,000 children younger than 5 years old in the hospital each year in the US. Sanofi and AstraZeneca’s antibody Beyfortus was approved in July, marking the first new treatment option for infants in decades.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
